GlucoTrack, Inc. (GCTK)
USD 0.23
(-5.78%)
USD 0.23
(-5.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.1 Million USD | -60.29% |
| 2022 | -4.43 Million USD | -9.7% |
| 2021 | -4.04 Million USD | -228.99% |
| 2020 | 3.13 Million USD | -10.66% |
| 2019 | 3.5 Million USD | -46.39% |
| 2018 | 6.53 Million USD | -38.17% |
| 2017 | 10.57 Million USD | 86.99% |
| 2016 | 5.65 Million USD | 21.49% |
| 2015 | 4.65 Million USD | 29.05% |
| 2014 | 3.6 Million USD | 19.14% |
| 2013 | 3.02 Million USD | 9.17% |
| 2012 | 2.77 Million USD | 218.86% |
| 2011 | -2.33 Million USD | -267.8% |
| 2010 | 1.39 Million USD | 18.83% |
| 2009 | 1.17 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.49 Million USD | -52.19% |
| 2024 Q1 | -2.95 Million USD | -22.09% |
| 2023 Q1 | -1.28 Million USD | 0.23% |
| 2023 Q4 | -2.41 Million USD | -208.73% |
| 2023 FY | -7.1 Million USD | -60.29% |
| 2023 Q3 | 2.22 Million USD | 288.55% |
| 2023 Q2 | -1.17 Million USD | 8.18% |
| 2022 Q1 | -1.09 Million USD | 27.33% |
| 2022 Q4 | -1.28 Million USD | -38.54% |
| 2022 Q3 | -929 Thousand USD | 17.28% |
| 2022 FY | -4.43 Million USD | -9.7% |
| 2022 Q2 | -1.12 Million USD | -2.74% |
| 2021 FY | -4.04 Million USD | -228.99% |
| 2021 Q2 | -873 Thousand USD | 2.57% |
| 2021 Q3 | -767 Thousand USD | 12.14% |
| 2021 Q4 | -1.5 Million USD | -96.09% |
| 2021 Q1 | -896 Thousand USD | -116.64% |
| 2020 Q4 | 5.38 Million USD | 706.99% |
| 2020 Q2 | -611.18 Thousand USD | -180.9% |
| 2020 Q1 | 755.49 Thousand USD | 24.71% |
| 2020 Q3 | -887.32 Thousand USD | -45.18% |
| 2020 FY | 3.13 Million USD | -10.66% |
| 2019 Q4 | 605.79 Thousand USD | -38.21% |
| 2019 Q2 | -894.3 Thousand USD | -187.24% |
| 2019 Q3 | 980.47 Thousand USD | 209.64% |
| 2019 Q1 | 1.02 Million USD | 1.35% |
| 2019 FY | 3.5 Million USD | -46.39% |
| 2018 Q3 | 1.61 Million USD | -19.7% |
| 2018 FY | 6.53 Million USD | -38.17% |
| 2018 Q4 | 1.01 Million USD | -37.22% |
| 2018 Q2 | 2 Million USD | 5.05% |
| 2018 Q1 | 1.9 Million USD | -28.73% |
| 2017 FY | 10.57 Million USD | 86.99% |
| 2017 Q4 | 2.67 Million USD | 1.19% |
| 2017 Q1 | 2.59 Million USD | 96.69% |
| 2017 Q2 | 2.64 Million USD | 1.87% |
| 2017 Q3 | 2.64 Million USD | 0.01% |
| 2016 Q1 | 1.26 Million USD | -18.69% |
| 2016 Q2 | 1.58 Million USD | 25.23% |
| 2016 FY | 5.65 Million USD | 21.49% |
| 2016 Q4 | 1.32 Million USD | -11.08% |
| 2016 Q3 | 1.48 Million USD | -6.13% |
| 2015 Q1 | 880.69 Thousand USD | -12.56% |
| 2015 Q3 | 1.12 Million USD | 2.49% |
| 2015 Q4 | 1.55 Million USD | 38.41% |
| 2015 Q2 | 1.09 Million USD | 24.47% |
| 2015 FY | 4.65 Million USD | 29.05% |
| 2014 Q4 | 1 Million USD | 221.24% |
| 2014 Q3 | -830.69 Thousand USD | -194.15% |
| 2014 Q2 | 882.32 Thousand USD | -0.55% |
| 2014 Q1 | 887.18 Thousand USD | 13.61% |
| 2014 FY | 3.6 Million USD | 19.14% |
| 2013 Q3 | 727.39 Thousand USD | -12.55% |
| 2013 Q4 | 780.88 Thousand USD | 7.35% |
| 2013 FY | 3.02 Million USD | 9.17% |
| 2013 Q1 | 687.82 Thousand USD | 0.34% |
| 2013 Q2 | 831.79 Thousand USD | 20.93% |
| 2012 Q2 | 754.07 Thousand USD | 16.37% |
| 2012 Q1 | 648 Thousand USD | 208.48% |
| 2012 FY | 2.77 Million USD | 218.86% |
| 2012 Q4 | 685.49 Thousand USD | -0.08% |
| 2012 Q3 | 686.02 Thousand USD | -9.02% |
| 2011 Q2 | 496.72 Thousand USD | -7.86% |
| 2011 Q4 | -597.35 Thousand USD | -185.31% |
| 2011 Q3 | 700.24 Thousand USD | 40.97% |
| 2011 Q1 | 539.12 Thousand USD | 0.0% |
| 2011 FY | -2.33 Million USD | -267.8% |
| 2010 FY | 1.39 Million USD | 18.83% |
| 2009 FY | 1.17 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 87.681% |
| AngioDynamics, Inc. | -97.71 Million USD | 92.73% |
| AtriCure, Inc. | -26.68 Million USD | 73.376% |
| Avinger, Inc. | -16.63 Million USD | 57.295% |
| Azenta, Inc. | -73.12 Million USD | 90.285% |
| BioLife Solutions, Inc. | -70.82 Million USD | 89.97% |
| The Cooper Companies, Inc. | 533.1 Million USD | 101.333% |
| Daxor Corporation | -177.07 Thousand USD | -3911.859% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 52.991% |
| Femasys Inc. | -14.5 Million USD | 51.035% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 475.079% |
| Hologic, Inc. | 882.6 Million USD | 100.805% |
| ICU Medical, Inc. | 22.82 Million USD | 131.124% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 100.402% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 30.828% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 119.158% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -2.948% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -2.948% |
| Masimo Corporation | 136.5 Million USD | 105.204% |
| Microbot Medical Inc. | -9.85 Million USD | 27.915% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 148.409% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 105.732% |
| Nephros, Inc. | -1.59 Million USD | -345.951% |
| NovoCure Limited | -232.87 Million USD | 96.949% |
| NEXGEL, Inc. | -3.47 Million USD | -104.314% |
| NEXGEL, Inc. | -3.47 Million USD | -104.314% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 93.09% |
| OraSure Technologies, Inc. | 54.07 Million USD | 113.136% |
| Pro-Dex, Inc. | 7.17 Million USD | 199.038% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 83.697% |
| Predictive Oncology Inc. | -13.92 Million USD | 48.97% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | -160.761% |
| QuidelOrtho Corporation | 139.1 Million USD | 105.107% |
| Repligen Corporation | 54.57 Million USD | 113.017% |
| Sanara MedTech Inc. | -4.21 Million USD | -68.535% |
| STAAR Surgical Company | 28.09 Million USD | 125.284% |
| Sharps Technology, Inc. | -10.12 Million USD | 29.848% |
| Utah Medical Products, Inc. | 16.77 Million USD | 142.344% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 91.642% |
| Jin Medical International Ltd. | 2.86 Million USD | 347.762% |